Sulfonylurea derivatives and cancer, friend or foe?Hendriks, A. M., Schrijnders, D., Kleefstra, N., de Vries, E. G. E., Bilo, H. J. G., Jalving, M. & Landman, G. W. D., 15-Oct-2019, In : European Journal of Pharmacology. 861, 12 p., 172598.
Research output: Contribution to journal › Review article › Academic › peer-review
Type 2 diabetes mellitus (T2DM) is associated with a higher risk of cancer and cancer-related mortality. Increased blood glucose and insulin levels in T2DM patients may be, at least in part, responsible for this effect. Indeed, lowering glucose and/or insulin levels pharmacologically appears to reduce cancer risk and progression, as has been demonstrated for the biguanide metformin in observational studies. Studies investigating the influence of sulfonylurea derivatives (SUs) on cancer risk have provided conflicting results, partly due to comparisons with metformin. Furthermore, little attention has been paid to within-class differences in systemic and off-target effects of the SUs. The aim of this systematic review is to discuss the available preclinical and clinical evidence on how the different SUs influence cancer development and risk. Databases including PubMed, Cochrane, Database of Abstracts on Reviews and Effectiveness, and trial registries were systematically searched for available clinical and preclinical evidence on within-class differences of SUs and cancer risk. The overall preclinical and clinical evidence suggest that the influence of SUs on cancer risk in T2DM patients differs between the various SUs. Potential mechanisms include differing affinities for the sulfonylurea receptors and thus differential systemic insulin exposure and off-target anti-cancer effects mediated for example through potassium transporters and drug export pumps. Preclinical evidence supports potential anti-cancer effects of SUs, which are of interest for further studies and potentially repurposing of SUs. At this time, the evidence on differences in cancer risk between SUs is not strong enough to guide clinical decision making.
|Number of pages||12|
|Journal||European Journal of Pharmacology|
|Early online date||10-Aug-2019|
|Publication status||Published - 15-Oct-2019|
- Type 2 diabetes mellitus, Sulfonylurea derivatives, Cancer, Gliclazide, Glibenclamide, TYPE-2 DIABETES-MELLITUS, TUMOR-CELL PROLIFERATION, POTASSIUM-ION CHANNELS, NECROSIS-FACTOR-ALPHA, BLOOD-GLUCOSE LEVELS, K-ATP CHANNELS, BREAST-CANCER, INSULIN-SECRETION, ANTIOXIDANT PROPERTIES, SERIOUS HYPOGLYCEMIA